Keng Chen1,2,3, Lin Huang1,2,3, Zhaopeng Cai1,2,3, Juntian Shi4, Kaiyun You4, Huiyong Shen5,6,7. 1. Department of Orthopaedics, Research Center of Spinal and Pelvic Tumour, Sun Yat-sen Memorial Hospital, Sun Yat-Sen University, 107 Yanjiang West Road, Guangzhou, 510120, China. 2. Research Institute for Spinal Cord Injury of Sun Yat-sen University, Guangzhou, 510120, China. 3. Research Center of Spinal and Spinal Cord Disease, Guangzhou, 510120, China. 4. Radiotherapy Department of Sun Yat-sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, 510120, China. 5. Department of Orthopaedics, Research Center of Spinal and Pelvic Tumour, Sun Yat-sen Memorial Hospital, Sun Yat-Sen University, 107 Yanjiang West Road, Guangzhou, 510120, China. shenhuiyong@aliyun.com. 6. Research Institute for Spinal Cord Injury of Sun Yat-sen University, Guangzhou, 510120, China. shenhuiyong@aliyun.com. 7. Research Center of Spinal and Spinal Cord Disease, Guangzhou, 510120, China. shenhuiyong@aliyun.com.
Abstract
PURPOSE: This is a retrospective analysis of the strategy and clinical results of surgery combined with intraoperative radiotherapy (IORT) to treat spinal metastases. METHODS: We delivered tumour-conformal IORT in 40 patients with 52 metastatic vertebrae based on our surgical classification system. The strategies were evaluated with respect to neurologic function and spinal stability. The EORTC QLQ-BM22, visual analogue scale (VAS) and the Frankel Scale were used to assess quality of life, pain and neurologic function. Local control was evaluated every 3 months using X-rays and MRI. RESULTS: Micro-invasive IORT was performed in 42 vertebrae (80.8%), and open surgery with IORT was performed in 10 vertebrae (19.2%). Single-level, 2-level and 3-level IORT was performed in 30, 8 and 2 cases, respectively. The delivered dose was 9.2 ± 3.6 Gy (8-15 Gy) with a depth of 10.1 ± 2.1 mm. The actual IORT treatment time was 5 min and 16 s. The follow-up period was 6-23 months (mean: 12.5 months). The local control rate was 92.3%. The EORTC QLQ-BM22 scores showed that patients had significant improvements in pain location, degree and function after treatment (P < 0.01). Thirty-five patients (89.7%) achieved pain relief throughout the follow-up period. VAS scores were significantly reduced by 3.4 points 3 months after treatment. Neurological function was improved in 7 patients (87.5%). No radiation-related complications were observed. CONCLUSIONS: Surgery combined with tumour-conformal IORT can effectively relieve pain, achieve good local control and improve QOL.
PURPOSE: This is a retrospective analysis of the strategy and clinical results of surgery combined with intraoperative radiotherapy (IORT) to treat spinal metastases. METHODS: We delivered tumour-conformal IORT in 40 patients with 52 metastatic vertebrae based on our surgical classification system. The strategies were evaluated with respect to neurologic function and spinal stability. The EORTC QLQ-BM22, visual analogue scale (VAS) and the Frankel Scale were used to assess quality of life, pain and neurologic function. Local control was evaluated every 3 months using X-rays and MRI. RESULTS: Micro-invasive IORT was performed in 42 vertebrae (80.8%), and open surgery with IORT was performed in 10 vertebrae (19.2%). Single-level, 2-level and 3-level IORT was performed in 30, 8 and 2 cases, respectively. The delivered dose was 9.2 ± 3.6 Gy (8-15 Gy) with a depth of 10.1 ± 2.1 mm. The actual IORT treatment time was 5 min and 16 s. The follow-up period was 6-23 months (mean: 12.5 months). The local control rate was 92.3%. The EORTC QLQ-BM22 scores showed that patients had significant improvements in pain location, degree and function after treatment (P < 0.01). Thirty-five patients (89.7%) achieved pain relief throughout the follow-up period. VAS scores were significantly reduced by 3.4 points 3 months after treatment. Neurological function was improved in 7 patients (87.5%). No radiation-related complications were observed. CONCLUSIONS: Surgery combined with tumour-conformal IORT can effectively relieve pain, achieve good local control and improve QOL.
Authors: Xin Shelley Wang; Laurence D Rhines; Almon S Shiu; James N Yang; Ugur Selek; Ibrahima Gning; Ping Liu; Pamela K Allen; Syed S Azeem; Paul D Brown; Hadley J Sharp; David C Weksberg; Charles S Cleeland; Eric L Chang Journal: Lancet Oncol Date: 2012-01-27 Impact factor: 41.316
Authors: Edward Chow; Amanda Hird; Galina Velikova; Colin Johnson; Linda Dewolf; Andrea Bezjak; Jackson Wu; Jesmin Shafiq; Orhan Sezer; Dimitrios Kardamakis; Yvette van der Linden; Brigette Ma; Monica Castro; Palmira Foro Arnalot; Sam Ahmedzai; Mark Clemons; Peter Hoskin; Albert Yee; Michael Brundage; Andrew Bottomley Journal: Eur J Cancer Date: 2008-12-25 Impact factor: 9.162
Authors: Vincenzo Valentini; Francesco Cellini; Bruce D Minsky; Gian Carlo Mattiucci; Mario Balducci; Giuseppe D'Agostino; Elisa D'Angelo; Nicola Dinapoli; Nicola Nicolotti; Chiara Valentini; Giuseppe La Torre Journal: Radiother Oncol Date: 2009-07-06 Impact factor: 6.280
Authors: Robert Krempien; Falk Roeder; Susanne Oertel; Jürgen Weitz; Frank W Hensley; Carmen Timke; Angela Funk; Katja Lindel; Wolfgang Harms; Markus W Buchler; Jürgen Debus; Martina Treiber Journal: Int J Radiat Oncol Biol Phys Date: 2006-05-06 Impact factor: 7.038
Authors: Frederik Wenz; Frank Schneider; Christian Neumaier; Uta Kraus-Tiefenbacher; Tina Reis; René Schmidt; Udo Obertacke Journal: Radiat Oncol Date: 2010-02-11 Impact factor: 3.481
Authors: Arjun Sahgal; Eshetu G Atenafu; Sam Chao; Ameen Al-Omair; Nicholas Boehling; Ehsan H Balagamwala; Marcelo Cunha; Isabelle Thibault; Lilyana Angelov; Paul Brown; John Suh; Laurence D Rhines; Michael G Fehlings; Eric Chang Journal: J Clin Oncol Date: 2013-08-19 Impact factor: 44.544